Duncan Higgons currently serves as a member of the Board of Directors for PsiOxus Therapeutics and Jounce Therapeutics. Mr. Higgons recently served as Chief Operating Officer of Agios Therapeutics. Prior to joining Agios, Mr. Higgons served as Executive Vice President, and interim president and Chief Executive Officer at Archemix Corporation. Prior to Archemix, Mr. Higgons served as the Chief Commercial Officer at TransForm Pharmaceuticals, a privately-held biotechnology company, which was acquired by Johnson & Johnson Company. Mr. Higgons holds a B.Sc. in Mathematics from King’s College University of London and an M.Sc. in Economics from London Business School.